Hemodynamic thresholds for precapillary pulmonary hypertension

Chest

Volumn 149, Issue 4, 2016, Pages 1061-1073

  Gerges, Christian ^a   Gerges, Mario ^a   Skoro Sajer, Nika ^a   Zhou, Yi ^b   Zhang, Lixia ^b   Sadushi Kolici, Roela ^a   Jakowitsch, Johannes ^a   Lang, Marie B ^a   Lang, Irene M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNITED THERAPEUTICS CORPORATION   (United States)

Author keywords

Heart failure; Hemodynamics; Pulmonary circulation; Pulmonary hypertension

Indexed keywords

PLACEBO; TREPROSTINIL; ANTIHYPERTENSIVE AGENT; PROSTACYCLIN;

ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC PULMONARY VASCULAR PRESSURE GRADIENT; FEMALE; HEART CATHETERIZATION; HUMAN; LUNG PRESSURE; LUNG WEDGE PRESSURE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; DIFFERENTIAL DIAGNOSIS; FACTUAL DATABASE; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HEMODYNAMICS; HYPERTENSION, PULMONARY; LUNG CIRCULATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; VASCULAR RESISTANCE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CARDIAC CATHETERIZATION; COHORT STUDIES; DATABASES, FACTUAL; DIAGNOSIS, DIFFERENTIAL; EPOPROSTENOL; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY CIRCULATION; PULMONARY WEDGE PRESSURE; RETROSPECTIVE STUDIES; ROC CURVE; VASCULAR RESISTANCE;

EID: 84964452505     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0928     Document Type: Article

References (41)

1. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44-54.
2. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106(21): 2666-2672.
3. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268-1277.
4. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebocontrolled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502-511.
5. Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146(5):1274-1285.
6. Vachiery JL, Adir Y, Barbera JA, et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol. 2013;62(25 suppl):D100-D108.
7. Hellems HK, Haynes FW, Dexter L. Pulmonary capillary pressure in man. J Appl Physiol. 1949;2(1):24-29.
8. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343-349.
9. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(21):2539-2550.
10. Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension. Chest. 2013;143(3): 758-766.
11. Gerges M, Gerges C, Pistritto AM, et al. Pulmonary hypertension in heart failure: epidemiology, right ventricular function and survival. Am J Respir Crit Care Med. 2015;192(10):1234-1246.
12. Naeije R, Vachiery JL, Yerly P, et al. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J. 2013;41(1):217-223.
13. Gerges C, Gerges M, Lang IM. Characterization of pulmonary hypertension in heart failure using the diastolic pressure gradient: the conundrum of high and low diastolic pulmonary gradient. JACC Heart Fail. 2015;3(5):424-425.
14. Lankhaar JW, Westerhof N, Faes TJ, et al. Quantification of right ventricular afterload in patients with and without pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2006;291(4): H1731-H1737.
15. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2): 164-172.
16. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156-163.
17. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58(24): 2511-2519.
18. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol. 2006;47(4):799-803.
19. LeVarge BL, Pomerantsev E, Channick RN. Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J. 2014;44(2): 425-434.
20. Kovacs G, Avian A, Pienn M, Naeije R, Olschewski H. Reading pulmonary vascular pressure tracings: how to handle the problems of zero leveling and respiratory swings. Am J Respir Crit Care Med. 2014;190(3):252-257.
21. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D42-D50.
22. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D34-D41.
23. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41(2):293-299.
24. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804.
25. Hiremath J, Thanikachalam S, Parikh K, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2): 137-149.
26. Stevens PM. Assessment of acute respiratory failure: cardiac versus pulmonary causes. Chest. 1975;67(1):1-2.
27. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845.
28. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant. 2015; 34(3):362-368.
29. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4): 780-788.
30. Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest. 2013;143(2):315-323.
31. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A metaanalysis of 22 randomized trials. J Am Coll Cardiol. 2012;60(13):1192-1201.
32. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012; 126(3):349-356.
33. Mlczoch J, Probst P, Szeless S, Kaindl F. Primary pulmonary hypertension: follow-up of patients with and without anorectic drug intake. Cor Vasa. 1980; 22(4):251-257.
34. Ryan JJ, Rich JD, Thiruvoipati T, Swamy R, Kim GH, Rich S. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J. 2012;163(4):589-594.
35. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest. 2009;136(1):37-43.
36. Frost AE, Farber HW, Barst RJ, Miller DP, Elliott CG, McGoon MD. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry. Chest. 2013;143:185-195.
37. Tedford RJ, Beaty CA, Mathai SC, et al. Prognostic value of the pre-transplant diastolic pulmonary artery pressure-topulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. J Heart Lung Transplant. 2014;33(3):289-297.
38. Tampakakis E, Leary PJ, Selby VN, et al. The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease. JACC Heart Fail. 2015;3(1):9-16.
39. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342(15):1077-1084.
40. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818.
41. Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124(2):164-174.